Nov 12, 2020 / 11:00PM GMT
Operator
Hello, and welcome to the presentation of the Phase Ib/II data of TG4001 plus avelumab in HPV16-positive cancers. My name is Jess, and I'll be your coordinator for today's event. (Operator Instructions)
I will now hand you over to your host, Lucie Larguier, to begin today's call. Thank you.
Lucie Larguier - Transgene SA - Director of Corporate Communications & IR
Thank you, Jess. Hello, everyone. I'm Lucie Larguier. Today with me are Philippe Archinard and Maud Brandely. And we are very excited to provide you with more details on the results we obtained with TG4001 in combination with avelumab in our Phase Ib/II trial.
Before I turn the call over to Mr. Archinard, I'd like to remind everyone that today's discussion contains forward-looking statements, which are subject to a number of risks and uncertainties. The presentation and the webcast can be accessed via the home page of our website and also on our Investor page. If you are listening to this webcast via Internet, you will not be able to ask questions. (Operator Instructions)
Transgene SA Presents Results From the Phase 1b/2 trial of TG4001 in Combination with Avelumab Conference Call Transcript
Nov 13, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers